Boswell Bruce A, Korol Anna, West-Mays Judith A, Musil Linda S
Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, OR 97239.
Department of Pathology and Molecular Medicine, McMaster University Health Science Centre, Hamilton, ON L8N 3Z5, Canada.
Mol Biol Cell. 2017 Apr 1;28(7):907-921. doi: 10.1091/mbc.E16-12-0865. Epub 2017 Feb 16.
The most common vision-disrupting complication of cataract surgery is posterior capsule opacification (PCO; secondary cataract). PCO is caused by residual lens cells undergoing one of two very different cell fates: either transdifferentiating into myofibroblasts or maturing into lens fiber cells. Although TGFβ has been strongly implicated in lens cell fibrosis, the factors responsible for the latter process have not been identified. We show here for the first time that TGFβ can induce purified primary lens epithelial cells within the same culture to undergo differentiation into either lens fiber cells or myofibroblasts. Marker analysis confirmed that the two cell phenotypes were mutually exclusive. Blocking the p38 kinase pathway, either with direct inhibitors of the p38 MAP kinase or a small-molecule therapeutic that also inhibits the activation of p38, prevented TGFβ from inducing epithelial-myofibroblast transition and cell migration but did not prevent fiber cell differentiation. Rapamycin had the converse effect, linking MTOR signaling to induction of fiber cell differentiation by TGFβ. In addition to providing novel potential therapeutic strategies for PCO, our findings extend the so-called TGFβ paradox, in which TGFβ can induce two disparate cell fates, to a new epithelial disease state.
白内障手术最常见的视力干扰并发症是后囊膜混浊(PCO;继发性白内障)。PCO是由残留的晶状体细胞经历两种截然不同的细胞命运之一所致:要么转分化为肌成纤维细胞,要么成熟为晶状体纤维细胞。尽管转化生长因子β(TGFβ)与晶状体细胞纤维化密切相关,但导致后一过程的因素尚未明确。我们在此首次表明,TGFβ可诱导同一培养物中的纯化原代晶状体上皮细胞分化为晶状体纤维细胞或肌成纤维细胞。标志物分析证实这两种细胞表型相互排斥。用p38丝裂原活化蛋白激酶的直接抑制剂或同样抑制p38活化的小分子疗法阻断p38激酶途径,可阻止TGFβ诱导上皮-肌成纤维细胞转化和细胞迁移,但不能阻止纤维细胞分化。雷帕霉素具有相反的作用,将哺乳动物雷帕霉素靶蛋白(mTOR)信号传导与TGFβ诱导的纤维细胞分化联系起来。除了为PCO提供新的潜在治疗策略外,我们的发现还将所谓的TGFβ悖论(即TGFβ可诱导两种不同的细胞命运)扩展到一种新的上皮疾病状态。